Diana Gallego

Ms. Diana Gallego

Centro de Diagnóstico de Enfermedades Moleculares, Center of Molecular Biology Severo Ochoa (CBMSO), Autonomous University of Madrid, CIBERER, Institute for Health Research IdiPAZ, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2020 in Human Mutation
Verified
Journal Article
Closed access
PDF file
DGDiana Gallego
Diana Gallego
FLFátima Leal
Fátima Leal
AGAlejandra Gámez
Alejandra Gámez
MCMargarita Castro
Margarita Castro
RNRosa Navarrete
Rosa Navarrete
BPBelen Perez
Belen Perez

1 November 2020 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
AGAlejandra Gámez
Alejandra Gámez
Mercedes SerranoMercedes Serrano
Mercedes Serrano
DGDiana Gallego
Diana Gallego
AVAlicia Vilas
Alicia Vilas
BPBelen Perez
Belen Perez

1 July 2020 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
AVA. Vilas
A. Vilas
PCPatricia Yuste Checa
Patricia Yuste Checa
DGDiana Gallego
Diana Gallego
LDL.R. Desviat
L.R. Desviat
MUM. Ugarte
M. Ugarte
BPBelen Perez
Belen Perez

Verified
Journal Article
Open access
PDF file
Elena RojanoElena Rojano
Elena Rojano
JCJosé Córdoba-Caballero
José Córdoba-Caballero
FJFernando M. Jabato
Fernando M. Jabato
DGDiana Gallego
Diana Gallego
Mercedes SerranoMercedes Serrano
Mercedes Serrano
PSPedro Seoane
Pedro Seoane
Exhaustive and comprehensive analysis of pathological traits is essential to understanding genetic diseases, performing precise diagnosis and prescribing personalized treatments. It is particularly important for disease cohorts, as thoroughly detailed phenotypic profiles allow patients to be compared and contrasted. However, many disease cohorts contain patients that have been ascribed low numbers of very general and relatively uninformative phenotypes. We present Cohort Analyzer, a tool that measures the phenotyping quality of patient cohorts. It calculates multiple statistics to give a general overview of the cohort status in terms of the depth and breadth of phenotyping, allowing us to detect less well-phenotyped patients for re-examining or excluding from further analyses. In addition, it performs clustering analysis to find subgroups of patients that share similar phenotypic profiles. We used it to analyse three cohorts of genetic diseases patients with very different properties. We found that cohorts with the most specific and complete phenotypic characterization give more potential insights into the disease than those that were less deeply characterised by forming more informative clusters. For two of the cohorts, we also analysed genomic data related to the patients, and linked the genomic data to the patient-subgroups by mapping shared variants to genes and functions. The work highlights the need for improved phenotyping in this era of personalized medicine. The tool itself is freely available alongside a workflow to allow the analyses shown in this work to be applied to other datasets.

Verified
Journal Article
Open access
PDF file
ASAlejandro Soriano-Sexto
Alejandro Soriano-Sexto
DGDiana Gallego
Diana Gallego
FLFátima Leal
Fátima Leal
NCNatalia Castejón-Fernández
Natalia Castejón-Fernández
RNRosa Navarrete
Rosa Navarrete
BPBelen Perez
Belen Perez
Inborn errors of metabolism (IEM) constitute a huge group of rare diseases affecting 1 in every 1000 newborns. Next-generation sequencing has transformed the diagnosis of IEM, leading to its proposed use as a second-tier technology for confirming cases detected by clinical/biochemical studies or newborn screening. The diagnosis rate is, however, still not 100%. This paper reports the use of a personalized multi-omics (metabolomic, genomic and transcriptomic) pipeline plus functional genomics to aid in the genetic diagnosis of six unsolved cases, with a clinical and/or biochemical diagnosis of galactosemia, mucopolysaccharidosis type I (MPS I), maple syrup urine disease (MSUD), hyperphenylalaninemia (HPA), citrullinemia, or urea cycle deficiency. Eight novel variants in six genes were identified: six (four of them deep intronic) located in GALE, IDUA, PTS, ASS1 and OTC, all affecting the splicing process, and two located in the promoters of IDUA and PTS, thus affecting these genes’ expression. All the new variants were subjected to functional analysis to verify their pathogenic effects. This work underscores how the combination of different omics technologies and functional analysis can solve elusive cases in clinical practice.

22 January 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
JCJosé Córdoba-Caballero
José Córdoba-Caballero
JPJames Perkins
James Perkins
FGFederico García-Criado
Federico García-Criado
DGDiana Gallego
Diana Gallego
ANAlicia Navarro-Sánchez
Alicia Navarro-Sánchez
JRJuan Antonio Ranea
Juan Antonio Ranea
A wide range of approaches can be used to detect micro RNA (miRNA)–target gene pairs (mTPs) from expression data, differing in the ways the gene and miRNA expression profiles are calculated, combined and correlated. However, there is no clear consensus on which is the best approach across all datasets. Here, we have implemented multiple strategies and applied them to three distinct rare disease datasets that comprise smallRNA-Seq and RNA-Seq data obtained from the same samples, obtaining mTPs related to the disease pathology. All datasets were preprocessed using a standardized, freely available computational workflow, DEG_workflow. This workflow includes coRmiT, a method to compare multiple strategies for mTP detection. We used it to investigate the overlap of the detected mTPs with predicted and validated mTPs from 11 different databases. Results show that there is no clear best strategy for mTP detection applicable to all situations. We therefore propose the integration of the results of the different strategies by selecting the one with the highest odds ratio for each miRNA, as the optimal way to integrate the results. We applied this selection-integration method to the datasets and showed it to be robust to changes in the predicted and validated mTP databases. Our findings have important implications for miRNA analysis. coRmiT is implemented as part of the ExpHunterSuite Bioconductor package available from https://bioconductor.org/packages/ExpHunterSuite.